Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.016
Sell
RSI(14)
33.926
Neutral
STOCH(KDJ)(9,3,3)
18.872
Neutral
ATR(14)
0.047
Low Volatility
CCI(14)
-123.398
Sell
Williams %R
77.807
Sell
TRIX(12,20)
-1.112
Sell
StochRSI(14)
66.536
Buy
KALA BIO Inc
KALA0.440USD
+0.041+10.28%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.27MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of KALA BIO Inc
Currency: USD Updated: 2026-02-06Key Insights
KALA BIO Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 202 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 1.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
KALA BIO Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
KALA BIO Inc Highlights
StrengthsRisks
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Overvalued
The company’s latest PE is -0.08, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.15M shares, increasing 25.38% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 91.01K shares of this stock.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.500
Target Price
+80.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of KALA BIO Inc is 6.82, ranking 205 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.56
Operational Efficiency
2.74
Growth Potential
6.77
Shareholder Returns
7.04
KALA BIO Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of KALA BIO Inc is 5.76, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -24730.86% below the recent high of 19.24 and -4123.05% above the recent low of -3.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 202/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of KALA BIO Inc is 6.00, ranking 340 out of 392 in the Biotechnology & Medical Research industry. The average price target is 1.50, with a high of 1.50 and a low of 1.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.500
Target Price
+80.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
KALA BIO Inc
KALA
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of KALA BIO Inc is 3.93, ranking 358 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.64 and the support level at 0.31, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.456
Sell
MA10
0.510
Sell
MA20
0.565
Sell
MA50
0.662
Sell
MA100
2.402
Sell
MA200
4.455
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of KALA BIO Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.48%, representing a quarter-over-quarter decrease of 63.81%. The largest institutional shareholder is The Vanguard, holding a total of 91.01K shares, representing 0.33% of shares outstanding, with 86.20% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Oxford Finance LLC
SR One Capital Management, LP
Baker Bros. Advisors LP
Woodline Partners LP
Adar1 Capital Management LLC
Geode Capital Management, L.L.C.
Kharabi (Darius)
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of KALA BIO Inc is 1.20, ranking 341 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -2.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-2.37
VaR
+9.58%
240-Day Maximum Drawdown
+97.97%
240-Day Volatility
+308.28%
Return
Best Daily Return
60 days
+42.63%
120 days
+42.63%
5 years
+218.37%
Worst Daily Return
60 days
-17.29%
120 days
-89.27%
5 years
-89.27%
Sharpe Ratio
60 days
-0.57
120 days
-1.18
5 years
-0.16
Risk Assessment
Maximum Drawdown
240 days
+97.97%
3 years
+97.97%
5 years
+99.90%
Return-to-Drawdown Ratio
240 days
-0.95
3 years
-0.33
5 years
-0.20
Skewness
240 days
-2.35
3 years
-1.81
5 years
+9.04
Volatility
Realised Volatility
240 days
+308.28%
5 years
+177.38%
Standardised True Range
240 days
+133.00%
5 years
+679.29%
Downside Risk-Adjusted Return
120 days
-127.32%
240 days
-127.32%
Maximum Daily Upside Volatility
60 days
+305.53%
Maximum Daily Downside Volatility
60 days
+102.16%
Liquidity
Average Turnover Rate
60 days
+2.24%
120 days
+1.58%
5 years
--
Turnover Deviation
20 days
+3.95%
60 days
+1.73%
120 days
-28.38%
Peer Comparison
Biotechnology & Medical Research
KALA BIO Inc
KALA
4.97 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
